The global medical coatings for implants market size is expected to reach USD 2,832.17 million by 2030. The market is expected to expand at a CAGR of 9.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2023 to 2030.
The growth is mainly driven by growing demand for medical implants for cardiovascular, dental, and orthopedics on the account of rising health issues related to bones, dental, and heart. Increase in incidence of orthopedic injuries, diseases such as arthritis, osteoarthritis, and the rapid rise in geriatric population are propelling the demand for orthopedic implants, further driving the demand for medical coatings.
Increasing elderly population, rising need for medical care of the aging population, rise in the prevalence of chronic disorders & diseases, and increasing healthcare expenditure is also augmenting the demand for medical coatings for implants.
Medical device coatings provide beneficial properties, including lubricity, flexibility, biocompatibility, antimicrobial, drug-eluting, and thromboresistance, to medical devices. The consumption for medical coatings has largely surged among manufacturers of cardiac arrest devices, catheters, feeding tubes, epidural probes, stents, guide wires, and other devices, which are to be inserted in the human body. These coatings provide high resistance against Healthcare Associated Infections (HAI), which is very common among people, who have been implanted with foreign devices for medical health care purposes.
The growing demand for coatings is expected to augment industry growth, as they improve biocompatibility between living tissues and medical devices. Rising preference for implantable and non-implantable medical equipment, along with growing number of private and public hospitals, is likely to fuel market growth. Technological innovation, such as introduction of antimicrobial microRESIST technology for orthopedic implants and catheters with anti-microbial properties, are further expected to foster market growth over the forecast period.
Healthcare expenditure in North America is likely to be driven by the rising prevalence of chronic diseases coupled with the expansion of insurance coverage in the U.S. The strengthening of the Western European economies is expected to result in high provision for healthcare expenditure in the annual budgetary proposals. The healthcare expenditure in Central & South America is expected to be driven by developments in the healthcare industry in Brazil. Moreover, healthcare industry in Asia is expected to be fueled by the growing consumer wealth in economies such as China and India. The presence of a well-developed healthcare industry in India coupled with growth of medical tourism is expected to augment the demand for medical coatings for implants.
Medical Coatings For Implants Market Report Highlights
Nanoparticle is the fastest growing product segment by revenue with an expected to expand at a CAGR of 10.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} on owing to the growing adaption of nano-technology in healthcare system
Physical Vapor Deposition (PVD) is the second fastest growing technology segment after others by revenue with an expected CAGR of 9.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} due to its properties such as corrosion resistance of metallic implants and it reduces allergic reactions
Dental implants is the fastest growing application segment by revenue with an expected CAGR of 10.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} due to growing demand for dental implants on the account of deteriorating teeth condition due to excessive consumption of junk food
Asia Pacific is the fastest growing region by revenue with a CAGR of 10.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} because of growing population in the region
Medical Coatings for Implants manufacturers are striving to elevate their production capacities in order to ensure regular supply of the product due to its growing demand from automotive industry
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The medical device analytical testing outsourcing market valued for $4,744.84 million in 2021 and is estimated to reach $7,956.99 million by 2031, exhibiting a CAGR of 5.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2022 to 2031.
Key factors driving the growth of the medical device analytical testing outsourcing market include growing need for medical testing and validation for medical devices and rise in adoption of analytical testing services such as physical testing, sterility testing, and others. In addition, rise in adoption of the medical devices such as cardiovascular devices, orthopedic devices, dental implants have led to increase the demand for analytical testing services for medical devices and further supports the growth of market.
Furthermore, rise in standards and regulations relating to services for medical device validation and verification stimulate the growth of the market. In addition, various initiatives by public organizations promoting the testing of medical devices drive the market growth.
Furthermore, Food Drug Administration (FDA) has regulated the guidelines, for ensuring the products quality, safety, and accuracy before its use. Hence, validation and medical testing is necessary for medical equipment which further contributes toward market growth.
Moreover, presence of well-established healthcare systems and rise in healthcare expenditure boost the market growth. Thus, increase in the prevalence of cardiovascular disease among population, presence of well-established healthcare systems, and rise in R&D activities for cardiovascular disease led to increases the demand for outsourcing of cardiovascular devices which contributes towards market growth.
The market also offers growth opportunities to the key players in the market. Rise in affordability of healthcare infrastructure and surge in medical expenditure in developing countries such as China, Japan, India and rise in healthcare spending this has led to surge in demand for medical devices analytical testing services, thereby provides the lucrative opportunity to the market growth. In addition, strong presence of pharmaceutical manufacturers in the developed countries are expected to create a positive impact on the market growth.
Furthermore, rise in health care expenditure significantly impacts growth of various pharmaceutical sectors in the healthcare industry. For instance, according to the Medicare and Medicaid Services, the National Health Expenditure (NHE) reached $3.8 trillion in 2019. The NHE increased by 4.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in 2019 and accounted for 17.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of the U.S. GDP.
Thus, increase in healthcare spending, surge in demand for medical devices analytical testing, owing to increase in prevalence of chronic diseases are expected to provide remunerative opportunities for expansion of the global medical device analytical testing outsourcing market during the forecast period.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the medical device analytical testing outsourcing market analysis from 2021 to 2031 to identify the prevailing medical device analytical testing outsourcing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the medical device analytical testing outsourcing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global medical device analytical testing outsourcing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments By Service
Physical Testing
Bioburden Testing
Sterility Testing
Others
By End User
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
SGS SA
Medistri SA
Element Materials Technology
Pace Analytical
North American Science Associates, LLC
The Smithers Group Inc.
Eurofins Scientific
Intetek Group plc
WuXi AppTec
Charles River Laboratories International, Inc.
Key Market Insights
By service, the others segment was the highest revenue contributor to the market in 2021 and is estimated to reach $3,812.71 million by 2031, with a CAGR of 4.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}. However, the sterility testing segment is estimated to be the fastest-growing segment with a CAGR of 7.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} during the forecast period.
By end user, the medical device manufacturer segment dominated the global market in 2021 and is expected to be the fastest-growing segment with a highest CAGR of 5.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} during the forecast period.
Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MEDICAL DEVICE ANALYTICAL TESTING OUTSOURCING MARKET, BY SERVICE
CHAPTER 5: MEDICAL DEVICE ANALYTICAL TESTING OUTSOURCING MARKET, BY END USER
CHAPTER 6: MEDICAL DEVICE ANALYTICAL TESTING OUTSOURCING MARKET, BY REGION
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The burden of neurological disorders is growing in the US and abroad, with neurological conditions representing the most frequent cause of disability worldwide1. The resulting consequences are considerable individual suffering and substantial societal healthcare costs2,3. R&D investments are needed to identify new therapies, but clinical research faces challenges including high costs, administrative hurdles, and challenging patient recruitment4,5,6. Furthermore, clinical trials and their associated follow-up visits burden patients and their relatives7, especially for those with highly disabling neurological diseases.
Against this backdrop, the use of digital tools, such as connected sensors, promises to make research more patient-centered and move clinical trials beyond single “snapshots” of disease status toward more continuous measurement of chronic disorders8. Connected digital products9 or Digital Health Technologies (DHTs)10,11 are software-containing, patient-focused, portable, and connected sensors of health-related measurements, which describe different products, including many wearables. DHT examples from current FDA guidance include spirometers with smart connectivity, consumer activity trackers, and mobile applications for patients to report outcomes11. Such connected sensors may improve both the quantity and quality of data collection during clinical trials and enable patient recruitment in a less burdensome and more patient-empowering remote setting9.
In neurological diseases such as Parkinson’s disease (PD), use of validated, reliable, and sensitive tools has already been shown to provide better data on the “real-life distribution of disease severity, as it fluctuates longitudinally” in early-stage patients12,13. DHTs can therefore facilitate new study designs12, improve the efficiency of clinical trials14,15,16, and contribute to tackling many of the challenges neurological research faces. As more researchers adopt such technologies, understanding the use and development of DHTs in neurological clinical trials will be valuable for investigators, practicing clinicians, and those designing patient care pathways. As such, this study documents trends in the use of DHTs in neurology research and highlights opportunities for both R&D activities and care delivery going forward.
We assessed studies registered on ClinicalTrials.gov for four exemplary chronic neurological disorders. Building on methods from Marra et al. (2020)9, we identified trial-indication pairs for clinical studies in epilepsy, the neuroinflammatory disease multiple sclerosis (MS), and the two neurodegenerative diseases, PD and Alzheimer’s disease (AD). We present quantitative and qualitative (categorical) analyses of the trials that used connected sensors to describe technology adoption in neurology research and outline underlying trends over the years 2010-2021, inclusive.
Of the 6763 trial-indication pairs for epilepsy, MS, AD, and PD considered, 503 trial-indication pairs were identified as using DHTs by our search algorithm. After manual verification, 441 trial-indication pairs, associated with 430 unique clinical trials, were determined to be relevant and included in the analysis sample (Supplementary Fig. 1). Analysis sample trial counts varied significantly across indications: most frequent were studies in PD (198, 44.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), followed by MS (119, 27.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), AD (87, 19.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and epilepsy (37, 8.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}).
We document growth in the use of DHTs in neurological clinical trials, with a compound annual growth rate of ~39{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2010 – 2020, consistent with trends in DHT growth that have been documented in registered clinical studies more broadly9. Most analyzed trials were interventional, with DHT trials based on registries having started only in recent years and typically incorporating some kind of digital activity or speech tracking (Fig. 1).
Fig. 1: Development of clinical trials for chronic neurological diseases by year of initiation, trial type and indication.
a Number of analyzed studies using Digital Health Technologies (DHTs) per year, stratified by the type of the respective trial. Line depicts the percentage of DHT trials out of all trials for the analyzed indications starting in the respective year. b Number of analyzed studies using DHTs per year, stratified by the indications epilepsy (Epi.), Alzheimer’s disease (AD), multiple sclerosis (MS), and Parkinson’s disease (PD). * Data for the year 2021 may be incomplete due to late registrations on ClinicalTrials.gov.
The relative frequency of DHT use in trials for the focal conditions increased from 0.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of trials in 2010 to 11.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in 2020. PD trials showed early uptake of DHTs and the highest use rate over the full period of the study (8.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} on average). AD, MS, and epilepsy trials showed a delayed upward trend, with respective use rates of 7.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}, 5.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}, and 3.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} overall (Supplementary Table 1).
Among all DHT trials, 16.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} included an industry sponsor or collaborator – slightly less frequently than the 19{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} previously documented across all medical disciplines9 – with industry partnerships more commonly observed in trials for epilepsy (37.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and AD (23.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) (see Supplementary Fig. 2).
With respect to studies’ categorical (qualitative) features, most trials tracked patient symptoms (91.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), with exceptions focusing on vital signs of caregivers or other disease-related outcomes such as medication adherence. The majority of trials measured motor functions (68.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), with many including exercise elements (34.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), sometimes through the use of gaming consoles (7.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}). Sleep (15.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), cognition (10.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and speech (4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) tracking were less common as were gamification (19.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), caregiver support (6.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and medication adherence (4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) elements (Table 1). A large share of studies used some form of mobile application (35.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and the most commonly referenced DHTs were wearables (129, 29.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), smartphones (76, 17.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), actigraphs (48, 10.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and mobile applications (42, 9.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) (see Supplementary Table 2).
Table 1 Qualitative (categorical) features of trials by indication.
PD and MS trials often focused on motor symptoms and physical exercise, with a high share of gamification elements in MS trials. Other observed characteristics included numerous caregiver support and speech recognition tools in AD trials, frequent sleep tracking in AD and epilepsy trials, cognition tracking in AD and MS trials, and a recurrent tracking of medication adherence in epilepsy trials (Table 1).
Generally, a trend toward more complex and more extensive studies was observed, as represented by a gradual change in categorical trial features over time (Fig. 2). Whereas the use of motor function and exercise tracking were already observed in 2010, speech and cognition tracking were not observed until the mid-2010s (Fig. 2). Speech and cognition tracking both grew over time and were present in 8.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} and 14.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of analyzed DHTs using trials in 2021, respectively (Supplementary Table 1). Conversely, the relative use of gamification elements decreased slightly in more recent years (Supplementary Table 1).
Fig. 2: Use of selected Digital Health Technology tracking modalities in trials registered on ClinicalTrials.gov for chronic neurological diseases by year of trial initiation.
Number of ClinicalTrials.gov registered trials of four different neurological indications using DHTs for different tracking modalities by trial initiation year (green bar plots). Additionally, rate of these studies compared to all trials for the same indications registered on ClinicalTrials.gov for the respective year is shown (orange line). Trials for the indications epilepsy, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease were included. a Absolute number and share of all trials for motor function tracking. b Absolute number and share of all trials for sleep tracking. c Absolute number and share of all trials for cognition tracking. d Absolute number and share of all trials for speech tracking. * Data for the year 2021 may be incomplete due to late registrations on clinicaltrials.gov.
Most registered trial-indication pairs were identified in North America or Europe, with a large share of trials having principal investigators in the US (209, 47.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), followed by Italy and France (both 28 or 6.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} each), the UK (19, 4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Belgium (17, 3.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Switzerland (16, 3.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Israel (14, 3.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Canada, Turkey, and Germany (all 13 or 2.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} each). In total, trials from 33 countries and all inhabited continents were included in the analysis sample. Some regions showed a local/regional concentration of DHT studies, often related to a specific indication. An interactive map displaying the locations of sample trials are publicly accessible at https://www.reine-nervensache.de/eigene-forschungsergebnisse/digital-health-technologies-in-neurology-trials.
Qualitatively, included studies displayed heterogeneity in their aims. Whereas some clinical trials aimed to validate products or novel biomarkers, others already applied them as endpoints in studies of other interventions.
While some have highlighted insufficient prospective clinical research applying DHTs and mobile health17, the use of DHTs in neurology trials has not previously been characterized in detail. We analyzed disease-specific DHT adoption in trials registered on ClinicalTrials.gov to provide insights specific to four chronic neurologic diseases.
The analysis confirmed a clear trend in DHT adoption, with some disease-specific heterogeneity. The earlier application of such tools in disorders with primarily motoric symptoms, such as PD or MS, is likely due to the early availability of wearable sensors to track motor functions and might contribute to the higher number of trials observed for these two indications. However, as novel sensors and sophisticated technical setups became available in more recent years, multimodal clinical trials tackling diverse research questions with DHTs began to emerge. This development is evident in the subset of AD trials, where recent growth in the share of trials using DHTs is consistent with increasing readiness of novel digital measures that integrate speech and cognition tracking18,19. In parallel, the repertoire of DHTs used in early-adopting subfields has also expanded, for example through potential PD monitoring technologies that now include passive tremor monitoring via wearables12,13, smartphone-based motor and vocal symptom assessments20,21, gait analysis via smart insoles22, and sensors for swallowing23.
Interestingly, pharmaceutical companies tested self-developed DHTs in some trials24,25,26, indicating a possibility for broader prospective adoption by other stakeholders. Differences in the share of industry-sponsored trials across neurologic diseases could indicate differences in experience with digital measures across indications or difference in research funding for different diseases (either within firms themselves and/or from investments by research foundations or public funders). Any of these factors could shape biopharmaceutical and medical device firms’ investments in their use in clinical trials. Regions with a higher density of clinical trials using DHTs differ in their indication-specificity, suggesting different backgrounds and foci of research teams: high-density areas with multiple indications were more frequent in the US and could indicate technology-driven research, whereas regional clusters focusing on research in a single indication appeared more common in other countries.
Some digital measures assessed in the analysis sample integrate information previously unavailable to clinicians and researchers, such as details of smartphone usage27 or characteristics of patient-caregiver-interactions28,29, in one case deploying real-time monitoring of mood and stress via a smart-home approach29. Monitoring cognitive and motor skills with ‘byproduct data’ such as metadata on smartphone keystroke dynamics, for example, in epilepsy27 or MS30, could allow remote monitoring to be passively and therefore more seamlessly integrated into patients’ daily lives and eventually, into clinical routines. Further examples of the use of previously inaccessible data for novel phenotyping include approaches such as longitudinal repetitive cognitive testing18,31, speech characterization32, or swallowing monitoring23. Especially in more complex recent studies, digital biomarkers or measures were observed in conjunction with biological and radiological biomarkers22,33, promising a more detailed overview of patients’ health status than ever before. Furthermore, the small but growing trend of monitoring and supporting caregivers or relatives via DHTs28,29 could preview new forms of promising assistance for these essential but often neglected alleviators of the burdens of chronic diseases. A personalized prevention of secondary burn-out or depression among caregivers could be supported by DHTs that objectively track interactions with patients and monitor caregivers’ vital signs and stress28,29.
The observed heterogenous use pattern of DHTs in the analysis sample highlights different use cases for validating DHTs, gathering data with DHTs, or using DHTs as interventions; understanding this heterogeneity should be a focus of future research. Examples of trials categorized by the use cases according to Marra et al.9 can be found in Supplementary Table 3. Generally, there appears to be a large variety of new therapeutic and monitoring solutions under study, although solutions often remain fragmented, stand-alone approaches, making it difficult to bring user-friendly, holistic approaches into practice at scale.
The growing share of disease-specific trials applying DHTs show that neurological research is already adapting and increasingly integrating remote digital measurements into its research agenda. In addition to growing adoption of established digital measures, such as motor function, novel approaches, such as speech and cognition tracking are being deployed more often.
Recent regulatory trends further support this development, as seen in the first qualification of a digital endpoint by the EMA in Duchenne muscular dystrophy34, a neuromuscular disorder, and published guidance for applying DHTs by the FDA11. Nevertheless, there remains ample opportunity to extend the use of DHTs in clinical trials and support their transition into routine clinical care. Different technologies promise improved patient healthcare access and new setups for decentralized clinical trials, thereby enabling previously unimaginable measures for gathering real-world evidence. Further research is needed to clarify what is required for broader adoption in practice, thus enabling the translation of verified, analytically validated, and clinically validated tools35 into improved patient care.
Methods
We identified DHTs in trials registered on ClinicalTrials.gov following Marra et al. (2020)9 and using an updated and curated version of the searched product list (see Supplementary Note 1 and GitHub repository in the Data Availability Statement). Additionally, trials were filtered for the conditions epilepsy, MS, AD, or PD, resulting in a dataset built around unique trial-indication pairs (only 10 trials had multiple indications). The analysis sample was restricted to trials launched from 2010–2021 (inclusive) that had at least begun recruitment. Data were retrieved on February 28th, 2022. The resulting set of records was analyzed for the use of DHTs and trials that referenced such products were included in the analysis and mapped to a list of relevant categories defined for this purpose. This list included non-mutually-exclusive features such as different tracking characteristics as listed in Table 1 and Supplementary Table 1 (mapping was carried out by L.M. and P.G.). For comparison, other contemporaneous trials for the same indications were pulled from ClinicalTrials.gov. All analyses were run using Python 3.8 (Python Software Foundation, Delaware, USA). An interactive map of the principal trial locations was generated using plotly version 5.4.036 after geocoding addresses with geopy version 2.2.037. The co-author team included a patient with one of the focal disorders.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The goal of this research analyze is to give investors, developers, organization executives, and marketplace individuals with in-depth investigation to allow for them to choose strategic initiatives and conclusions associated to the potential customers in the global medical unit analytical screening companies marketplace. This report provides and analyzes the significant traits widespread in the global health care machine analytical tests expert services market and the current market measurement and forecast.
Clinical products are issue to stringent rules and handle specs. Improvement, introduction, and use of normal complying healthcare products be certain efficacy and safety of these kinds of products. A number of regulatory authorities and companies often collaborate to established standards for health care gadgets. These institution of criteria involves developing overall performance qualities, tests techniques, production practices, solution characters and benchmarks, use protocols, ingredient technical specs, labeling, and other such criteria.
This report categorizes the world wide health care gadget analytical tests companies market in phrases of services variety and geographical distribution. Based on provider sort, the world-wide health care gadget analytical screening services industry is classified into content characterization, extractable & leachable testing, bodily tests, sterility testing, bioburden testing, and other people. Current market measurement and forecast for each individual described phase for the interval 2020-2030 is introduced in the report along with respective CAGRs for the forecast duration 2022-2030.
The current market dimension and forecast of just about every regarded geographical market are presented for the time period 2020-2030 together with CAGRs for the forecast period of time 2022-2030 in this research and are further more cross-sectional introduced in conditions of service sort, and constituent region/country level marketplaces.
Among the the considered provider forms, product characterization retains the most significant revenue share in the all round health care machine analytical screening companies market. Through product characterization expert services, the service suppliers guidance medical gadget companies in setting up biocompatibility by identification and quantification of substances in products. Product characterization is carried out to determine content toxicity and generally follows ISO 10993-18 techniques.
The initial machines producers in North America and Europe have an extra worry of that contains over-all business expenditure while concurrently concentrating on main competency of the development of novel healthcare devices. This has led the professional medical unit companies in these regions to progressively outsource their non-core procedures to third-occasion assistance vendors. Furthermore, as the healthcare infrastructure in Asia Pacific is correspondingly developing to the ever-growing affected individual pool, the Asia Pacific industry is presenting valuable current market penetration opportunities to the multinational giants.
Current market Segmentation Provider Style
Essential queries answered in this report
What are the essential micro and macro environmental variables that are impacting the expansion of Health-related System Analytical Testing Expert services market place?
What are the important expense pockets with regard to products segments and geographies now and all through the forecast interval?
Believed forecast and market place projections up to 2030.
Which section accounts for the quickest CAGR throughout the forecast interval?
Which current market section holds a larger sector share and why?
Are low and middle-earnings economies investing in the Clinical Unit Analytical Screening Products and services sector?
Which is the greatest regional market for Medical Product Analytical Tests Expert services marketplace?
What are the market place tendencies and dynamics in rising markets these types of as Asia Pacific, Latin America, and Center East & Africa?
Which are the essential trends driving Professional medical Product Analytical Testing Services current market progress?
Who are the important competitors and what are their essential strategies to enhance their current market existence in the Medical Machine Analytical Tests Providers sector worldwide?
Critical Subjects Included:
1. Preface
2. Government Summary
3. Professional medical Device Analytical Testing Expert services Industry: Aggressive Investigation
4. Health care Unit Analytical Testing Solutions Market place: Macro Assessment & Marketplace Dynamics
5. Health care Machine Analytical Testing Services Current market: By Provider Kind, 2020-2030, USD (Million)
6. North America Medical Product Analytical Testing Expert services Current market, 2020-2030, USD (Million)
7. United kingdom and European Union Health care Unit Analytical Screening Solutions Sector, 2020-2030, USD (Million)
8. Asia Pacific Healthcare Unit Analytical Screening Companies Market, 2020-2030, USD (Million)
9. Latin The usa Medical Gadget Analytical Tests Services Market, 2020-2030, USD (Million)
10. Center East and Africa Healthcare Product Analytical Testing Companies Marketplace, 2020-2030, USD (Million)
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s primary supply for intercontinental market place exploration reports and market place data. We provide you with the newest information on global and regional marketplaces, critical industries, the leading providers, new goods and the most up-to-date tendencies.
Make contact with: Make contact with: ResearchAndMarkets.com Laura Wooden,Senior Push Supervisor press@researchandmarkets.com For E.S.T Business Hours Simply call 1-917-300-0470 For U.S./ CAN Toll Cost-free Connect with 1-800-526-8630 For GMT Office Several hours Simply call +353-1-416-8900
SafeRide Overall health, the leading technological know-how-first platform connecting patients to treatment, announced these days the launch of 19 new Medicare Benefit partnerships and development into six new markets.
Through a historic begin to 2023, offering rides to millions of Medicare and Medicaid members, SafeRide launched the very first-of-its-sort self-managed transportation application. The plan empowers wellbeing ideas to deliver transportation benefit management in-household with increased management and oversight of the member experience – backed by the assistance and know-how of SafeRide’s intuitive and scalable technologies system. Whether clientele decide on SafeRide’s self-managed or fully-managed transportation method choices, they profit from real-time insights that travel member experience metrics that enable strengthen vital Centers for Medicare & Medicaid (CMS) Star Rating metrics like member pleasure, gains utilization, and grievance premiums.
“At SafeRide, we’re driven by the mission of restoring accessibility and dignity to care, just one journey at a time. In 2022, we scaled that mission with our companions and remodeled the high-quality and encounter of plenty of rides to daily life-sustaining treatment,” reported Robbins Schrader, CEO and Co-founder of SafeRide Health and fitness. “As we start off 2023, we’re thrilled to increase with foremost associates who see accessibility to care as a vital approach to addressing Social Determinants of Health.”
SafeRide continues to refresh healthcare logistics as 1 of the 1st vendors to integrate rideshare companies as a frictionless, contemporary way for users to ask for pre-licensed rides at their comfort. Current info from Lyft confirmed SafeRide assisted lessen no-demonstrate charges by 63 per cent and lowered get in touch with centre volume by 30 percent with rideshare added benefits.
“This past calendar year, we saw large results, and we’re thrilled to see even additional indicators of expansion by way of 19 new well being approach partnerships, eight new states and more than 500 new NEMT suppliers. We’re very pleased to now provide above four million associates across the nation,” mentioned Andy Auerbach, Chief Revenue Officer of SafeRide. “These application launches just about double the amount of lives our know-how touches, and that signifies together with our companions, we’re supporting near the gap concerning require and obtain for some of the most susceptible populations.”
Studies estimate that 14 {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} or a single in 8 seniors in the U.S. will not have enough obtain to non-unexpected emergency treatment in 2023. In comprehension the collective demands of the populations they serve, foremost health and fitness payors like Alignment Health Approach are doing the job to overcome these studies by partnering with SafeRide to give a variety of NEMT services, including on-demand transportation. The new Medicare Edge advantage noticed quick adoption, with 20 per cent of every month rides currently being fulfilled on-demand inside of two hours of the request.
To master extra about implementing technology-1st NEMT providers, go to www.saferidehealth.com.
About SafeRide Wellbeing
SafeRide Wellness is a engineering and providers enterprise dedicated to cutting down obstacles to treatment by strengthening the supply of non-crisis medical transportation to folks across America. SafeRide Overall health leverages proprietary technologies and a nationwide network of vetted transportation companies to give payers and wellness units a additional intelligent way to supply cost-successful, on-demand transportation though improving the client practical experience. SafeRide serves the biggest Medicare Benefit, Medicaid, and provider systems in the nation. Learn a lot more at www.saferidehealth.com.
The U.S. actual physical remedy digital and telerehabilitation providers current market is estimated to be valued at US$ 142.2 million in 2023 and anticipated to show a CAGR of 13.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} during the forecast period (2023-2030).
Coherent Current market Insights Published Most the latest U.S. Bodily Remedy Virtual and Telerehabilitation Providers Market place Examine by in-depth examination of the current state of affairs, the Current market sizing, demand, development pattern, trends, and forecast. This report on the examine considers crucial elements these as an investigation of the industry, a definition of the marketplace, industry segmentation, considerable developments in the sector, an examination of the competitive landscape, and study methodology. For obtaining amazing progress in business, this U.S. Physical Treatment Virtual and Telerehabilitation Companies industry research report performs a quite central function. With the unique foundation yr and the historic yr, particular estimations and calculations are carried out in this U.S. Bodily Treatment Digital and Telerehabilitation Solutions report.
Telerehabilitation is the shipping of rehabilitation solutions using data and conversation systems remotely. Telerehabilitation will help individuals to interact with healthcare professionals remotely and support in assessing patients and offering treatment.
Telerehabilitation is a instrument that can help in achieving out to people in remote regions and rehabilitate ailments. Tele-Physio-Remedy utilizes networking applications for helping people in acquiring physiotherapy in their residences, as a result of video clip or audio calls. Tele-Physio-Therapy provides various recovery and rehabilitation courses in medical center and clinics.
Edition: 2023
Scope of U.S. Bodily Remedy Virtual and Telerehabilitation Expert services for 2023:
U.S. Bodily Remedy Virtual and Telerehabilitation Companies Marketplace investigate assesses the amount of development and current market price based mostly on current market dynamics and expansion creating variables. Entire knowledge is based mostly on the most latest industry information, potential customers, and developments. The investigate incorporates a extensive industry investigation and vendor landscape, as nicely as a SWOT analysis of the prime participant.
Table of Contents (Scope included as a element of the examine)
Best players in the market
Investigate framework (composition of the report)
Exploration methodology adopted by Coherent Market place Insights
Important providers in U.S. Actual physical Treatment Digital and Telerehabilitation Providers Market place are:
MTI The united states, VPT (Digital Bodily Therapists), Conversa Wellness, MindStreet, Inc., MEDRISK, Worldwide Outreach TeleRehabilitation Providers, Inc., Empatha, GestureTek Inc., Neuro Rehab Vr, American Very well, LiteGait, Medical doctor On Need, Inc., Hinge Wellbeing, Inc., Care Improvements LLC., and Jintronix
In addition, this report discusses the significant aspects influencing marketplace expansion as well as the opportunities, pitfalls, and troubles that the business as a entire and important rivals in specific deal with. It also appears to be at vital new traits and how they could possibly have an impact on equally present and future development.
The in-depth overview of the U.S. Actual physical Remedy Digital and Telerehabilitation Services market’s new developments, controversial developments, market place pilots by now in spot, challenges, norms, and complex domain.
Industry Segmentation:
By Company Sort: Audio, Video clip, Both
By Application: Cardiovascular Actual physical Therapy, Orthopedic Actual physical Therapy, Neurological Bodily Treatment, Strain Ulcers, Cognitive Rehabilitation, Other individuals
By Close Person: Hospitals, Rehabilitation Centers, Homecare Configurations, Others
U.S. Actual physical Remedy Digital and Telerehabilitation Services Marketplace 2022 Critical Insights:
Perform exploration and analysis on the state of the U.S. Physical Treatment Virtual and Telerehabilitation Solutions market, as perfectly as its potential prospective customers for creation, selling price structure, intake, and historical details.
By pinpointing the quite a few segments and sub-segments of the U.S. Actual physical Treatment Digital and Telerehabilitation Products and services Industry, the analyze clarifies the composition of the industry.
Current market historic data from 2017 to 2022 and forecast to 2030, damaged down by company, products and solutions, stop-buyers, and crucial nations.
An evaluation of the key phrase market’s personal growth styles, prospective buyers for the upcoming, and contribution to the full search phrase sector.
The U.S. Bodily Remedy Digital and Telerehabilitation Companies Market 2023 report examines business enterprise promotions, the introduction of new merchandise, and U.S. Bodily Treatment Digital and Telerehabilitation Solutions Current market acquisition.
Essential international companies in the U.S. Physical Therapy Digital and Telerehabilitation Solutions Current market are the concentrate of this study’s endeavor to profile them in terms of income quantity, revenue, progress prospective clients, motivators, SWOT investigation, and long run advancement programs.
Highlights of the U.S. Physical Therapy Virtual and Telerehabilitation Services report:
A entire backdrop examination, which includes an assessment of the U.S. Physical Therapy Digital and Telerehabilitation Providers Industry
An goal evaluation of the trajectory of the market place
Current market segmentation up to the 2nd or third level
Reporting and analysis of recent sector developments
Critical changes in market dynamics
Emerging specialized niche segments and regional markets
Historic, present, and projected dimensions of the market place from the standpoint of equally benefit and quantity
Current market shares and techniques of key gamers
Recommendations to organizations for strengthening their foothold in the market place
The study was compiled based mostly on the synthesis, assessment, and knowing of details collected from several resources on the mum or dad market place. On top of that, the financial problems and other financial indicators and determinants have been analyzed in purchase to analyse their respective affect on the U.S. Bodily Therapy Digital and Telerehabilitation Solutions Market, as perfectly as the existing influence, in purchase to deliver strategic and knowledgeable forecasts regarding the market scenarios. This is typically due to the developing world’s unmet potential in phrases of product or service pricing and income development.
Coherent Market place Insights is a world market intelligence and consulting group focused on helping our myriad of customers realize transformational growth by assisting them make crucial company selections. We are headquartered in India, having income office environment at worldwide financial money in the U.S. and income consultants in United Kingdom and Japan. Our shopper foundation incorporates gamers from throughout a variety of business verticals in around 57 international locations throughout the world. We create value for customers by means of our very trusted and correct experiences. We are also fully commited in actively playing a foremost function in providing insights in several sectors submit-COVID-19 and carry on to provide measurable, sustainable final results for our consumers.
